Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(154 productos)
- Bcr-Abl(111 productos)
- EGFR(591 productos)
- FAK(71 productos)
- FLT(87 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(173 productos)
- JAK(245 productos)
- PDGFR(126 productos)
- RAAS(89 productos)
- Src(81 productos)
- Syk(37 productos)
- Trombina(52 productos)
- VDA(2 productos)
- VEGFR(253 productos)
Mostrar 6 subcategorías más
Se han encontrado 1884 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Tyrphostin 63
CAS:Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.Fórmula:C10H8N2OForma y color:SolidPeso molecular:172.183JAK1-IN-9
CAS:JAK1-IN-9 (compound 23a) is a potent, selective inhibitor of JAK1, demonstrating an IC50 of 72 nM.Fórmula:C16H13IN6Forma y color:SolidPeso molecular:416.22Si306
CAS:Si306, an Src inhibitor, exhibits antitumor activity by reducing the phosphorylation of focal adhesion kinase (FAK) and the expression of epidermal growth factor receptor (EGFR), thereby inhibiting the invasion of human glioblastoma (GBM).Fórmula:C25H26BrClN6OSForma y color:SolidPeso molecular:573.94FGFR1 inhibitor-16
CAS:<p>FGFR1inhibitor-16 (Compound 89) functions as an FGFR1 inhibitor, demonstrating an inhibition rate of 53.00% at a concentration of 50 μM and 24.95% at 10 μM. It is utilized in tumor research.</p>Fórmula:C16H9N5O3SForma y color:SolidPeso molecular:351.339FAK-IN-3
<p>FAK-IN-3 inhibits FAK, reduces PA-1 cell migration/invasion, and tumor growth, with no major side effects.</p>Fórmula:C28H28N6O4Forma y color:SolidPeso molecular:512.56Protein Kinase Inhibitor 12
CAS:<p>Protein Kinase Inhibitor 12 (compound 1-91) is protein kinase inhibitor,PIM-1, CDK-2, GSK-3, and SRC mammalian protein kinases.</p>Fórmula:C14H14N4OSPureza:98.06%Forma y color:SolidPeso molecular:286.35BTK-IN-6
BTK-IN-6, a potent BTK inhibitor, may treat immune, cardiac, cancer, viral, inflammatory, metabolic, and neurological disorders.Fórmula:C23H22FN5O3Forma y color:SolidPeso molecular:435.45(S)-3-Hydroxy Midostaurin
CAS:(S)-3-Hydroxy Midostaurin is a potent inhibitor of kinases(IC50 of <400 nM for 13 kinases (VEGFR-2, TRK-A, FLT3, et)).Fórmula:C35H30N4O5Pureza:98%Forma y color:SolidPeso molecular:586.64JAK2/FLT3-IN-1 TFA
JAK2/FLT3-IN-1 (TFA), an oral JAK2/FLT3 inhibitor, shows anticancer properties; IC50: JAK2 (0.7 nM), FLT3 (4 nM), JAK1 (26 nM), JAK3 (39 nM).Fórmula:C27H35F4N7O3Forma y color:SolidPeso molecular:581.61HER2-IN-7
CAS:HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.Fórmula:C28H26F3N7O3Forma y color:SolidPeso molecular:565.55VEGFR-IN-3
CAS:VEGFR-IN-3 inhibits cancer cell growth (OVCAR-4, MDA-MB-468) with IC50s: 0.29, 0.35μM. Used in cancer research.Fórmula:C27H28N2O6Forma y color:SolidPeso molecular:476.52FGFR4-IN-9
FGFR4-IN-9 is a selective inhibitor of FGFR4 (IC50: 75.3 nM) that effectively inhibits the growth and angiogenesis of hepatocellular carcinoma cells.Fórmula:C24H22ClF3N4O4Forma y color:SolidPeso molecular:522.9JBJ-02-112-05
CAS:JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].Fórmula:C27H20N4O2SPureza:98%Forma y color:SolidPeso molecular:464.54RGB-286638
CAS:RGB-286638 inhibits multiple CDKs and GSK-3β, TAK1, Jak2, MEK1 with IC50s as low as 1-54 nM.Fórmula:C29H37Cl2N7O4Forma y color:SolidPeso molecular:618.55TQ-3959
CAS:TQ-3959 is an orally active BTKPROTAC degrader, with a DC50 of 14.6 nM. It exhibits antiproliferative activity against both wild-type BTK and BTK C481S mutant cell lines. TQ-3959 demonstrates tumor growth inhibition in female NOD-SCID mice with TMD-8 xenografts. This compound is applicable in the study of B-cell malignancies, such as lymphoma.Fórmula:C40H47N11O5Forma y color:SolidPeso molecular:761.87HER2-IN-12
HER2-IN-12 is an HER2 inhibitor with an IC50 value of 121 nM and can be used to study cancers such as breast cancer.Fórmula:C17H18BrN5O2SForma y color:SolidPeso molecular:436.33JAK-2/3-IN-3
JAK-2-/3-IN-3 (ST4j) is a potent JAK2/3 inhibitor for leukemia research, with IC50s: JAK2, 13 nM; JAK3, 14.86 nM; induces apoptosis.Fórmula:C13H10Cl2N4O2Forma y color:SolidPeso molecular:325.15WDR5-MYC-IN-2
CAS:WDR5-MYC-IN-2 is an inhibitor of the WDR5-MYC protein-protein interaction (PPI) with an IC50 of 0.59 μM. It is utilized in research on MYC-driven cancers and in the development of other potent WDR5-MYC PPI inhibitors.Fórmula:C22H20BrClN4O4SForma y color:SolidPeso molecular:551.84EGFR-IN-23
CAS:EGFR-IN-23, identified as compound 8 in WO2021244502A1, is a potent EGFR tyrosine kinase inhibitor (TKI) demonstrating an inhibitory concentration (IC50) of 8.Fórmula:C36H44BrN10O3PForma y color:SolidPeso molecular:775.68GNE-431
CAS:GNE-431: potent, selective noncovalent Btk inhibitor, IC50=3.2 nM; effective against C481R, T474I, T474M mutants, may counter ibrutinib resistance.Fórmula:C30H32N10O2Forma y color:SolidPeso molecular:564.64
